{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:27:04Z","timestamp":1792153624144,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.apjo.2025.100144","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T19:23:30Z","timestamp":1736969010000},"page":"100144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-6220","authenticated-orcid":false,"given":"Paisan","family":"Ruamviboonsuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny S.C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voraporn","family":"Chaikitmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1578","authenticated-orcid":false,"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-8817","authenticated-orcid":false,"given":"Fumi","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg T.","family":"Kokame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Y.C.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2025.100144_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.apjo.2025.100144_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100144_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100144_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.86.3.321","article-title":"Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation","volume":"86","author":"Terasaki","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib5","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1167\/iovs.08-2134","article-title":"Clinicopathologic findings in polypoidal choroidal vasculopathy","volume":"49","author":"Nakashizuka","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2023.100003","article-title":"Genetic associations of central serous chorioretinopathy subtypes, neovascular age-related macular degeneration, and polypoidal choroidal vasculopathy","volume":"13","author":"Chen","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","volume":"15","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","article-title":"Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy","volume":"158","author":"De Salvo","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bjophthalmol-2013-304658","article-title":"En-face high-penetration optical coherence tomography imaging in polypoidal choroidal vasculopathy","volume":"99","author":"Sayanagi","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","article-title":"Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration","volume":"118","author":"Chung","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IAE.0000000000001346","article-title":"Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness","volume":"36","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.iae.0000249386.63482.05","article-title":"Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy","volume":"27","author":"Sato","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib15","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.apjo.2025.100144_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the planet study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.apjo.2025.100144_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/APO.0000000000000602","article-title":"Review on the safety and efficacy of brolucizumab for neovascular age-related macular degeneration from major studies and real-world data","volume":"12","author":"Radke","year":"2023","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100144_bib21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol","year":"2021","journal-title":"Asia Pac J Ophthalmol (Philos"},{"key":"10.1016\/j.apjo.2025.100144_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ins.2018.02.003","article-title":"Measuring consensus and dissensus: a generalized index of disagreement using conditional probability","volume":"439-440","author":"Tsuchiya","year":"2018","journal-title":"Inf Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.apjo.2025.100144_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.apjo.2025.100144_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1755-3768.2009.01517.x","article-title":"Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy","volume":"88","author":"Byeon","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib26","article-title":"Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings","volume":"52","author":"Khan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): A lesson in the taxonomy of 'expanded spectra' - a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00417-017-3591-3","article-title":"Choroidal structures in polypoidal choroidal vasculopathy, neovascular age-related maculopathy, and healthy eyes determined by binarization of swept source optical coherence tomographic images","volume":"255","author":"Bakthavatsalam","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib29","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/IAE.0000000000001481","article-title":"Detailed characterization of choroidal morphologic and vascular features in age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"37","author":"Gupta","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/IAE.0000000000000742","article-title":"En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography","volume":"36","author":"Dansingani","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1167\/iovs.16-20519","article-title":"Classification of exudative age-related macular degeneration with pachyvessels on en face swept-source optical coherence tomography","volume":"58","author":"Ng","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000774","article-title":"Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many?","volume":"36","author":"Balaratnasingam","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100144_bib34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ophtha.2017.02.006","article-title":"Impact of multiple en face image averaging on quantitative assessment from optical coherence tomography angiography images","volume":"124","author":"Uji","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ophtha.2013.10.014","article-title":"En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy","volume":"121","author":"Ferrara","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ceo.13984","article-title":"Visualising the choriocapillaris: histology, imaging modalities and clinical research - A review","volume":"50","author":"Ng","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11154614","article-title":"Relationship between pachychoroid and polypoidal choroidal vasculopathy","volume":"11","author":"Yamashiro","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.apjo.2025.100144_bib38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/aos.14683","article-title":"Pachychoroid spectrum disease","volume":"99","author":"Borooah","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000503834","article-title":"Clinical characteristics of polypoidal choroidal vasculopathy and anti-vascular endothelial growth factor treatment response in caucasians","volume":"243","author":"Kokame","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.apjo.2025.100144_bib40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","article-title":"Anti\u2013vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy","volume":"3","author":"Kokame","year":"2019","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2025.100144_bib41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/08820538.2018.1506483","article-title":"Prevalence and risk factors for polypoidal choroidal vasculopathy in a general Japanese population: the Hisayama study","volume":"33","author":"Fujiwara","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/aos.14655","article-title":"Association between C-reactive protein and polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"99","author":"Borgersen","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/jhg.2017.83","article-title":"Shared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East Asians","volume":"62","author":"Fan","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.apjo.2025.100144_bib44","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ophtha.2015.05.012","article-title":"Association of genetic variants with polypoidal choroidal vasculopathy: a systematic review and updated meta-analysis","volume":"122","author":"Ma","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/APO.0000000000000573","article-title":"Polypoidal choroidal vasculopathy: updates on risk factors, diagnosis, and treatments","volume":"12","author":"Ruamviboonsuk","year":"2023","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100144_bib46","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib47","first-page":"417","article-title":"Criteria for diagnosis of polypoidal choroidal vasculopathy","volume":"109","author":"Japanese Study Group of Polypoidal Choroidal V","year":"2005","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.apjo.2025.100144_bib48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaophthalmol.2019.0565","article-title":"Sensitivity and specificity of potential diagnostic features detected using fundus photography, optical coherence tomography, and fluorescein angiography for polypoidal choroidal vasculopathy","volume":"137","author":"Chaikitmongkol","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib49","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IAE.0000000000000794","article-title":"Distinguishing polypoidal choroidal vasculopathy from typical neovascular age-related macular degeneration based on spectral domain optical coherence tomography","volume":"36","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib50","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","article-title":"EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy","volume":"99","author":"Tan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.oret.2021.04.002","article-title":"Non-ICGA treatment criteria for suboptimal anti-VEGF response for polypoidal choroidal vasculopathy: APOIS PCV workgroup report 2","volume":"5","author":"Chong Teo","year":"2021","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2025.100144_bib52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results","volume":"156","author":"Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2025.100144_bib54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study","volume":"65","author":"Ogura","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib55","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3928\/15428877-20090430-14","article-title":"Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy","volume":"40","author":"Kim","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.apjo.2025.100144_bib56","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1167\/iovs.02-0604","article-title":"Sequence of early vascular events after photodynamic therapy","volume":"44","author":"Michels","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib57","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archopht.123.10.1347","article-title":"Complications after photodynamic therapy","volume":"123","author":"Schnurrbusch","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","article-title":"Photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Nowak-Sliwinska","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2025.100144_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.iae.0000231544.43093.40","article-title":"Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection","volume":"27","author":"Gopalakrishan","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib60","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0161-6420(01)00648-0","article-title":"Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions","volume":"108","author":"Hattenbach","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib61","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0161-6420(99)90399-8","article-title":"Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement","volume":"106","author":"Hassan","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib62","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archopht.116.10.1326","article-title":"Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator","volume":"116","author":"Ohji","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-024-06671-y","article-title":"Submacular hemorrhage: my personal journey to the goal","author":"Ohji","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2025.100144_bib64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5301\/ejo.5000135","article-title":"Combination therapy with focal laser photocoagulation and intravitreal ranibizumab for polypoidal choroidal vasculopathy: a case series","volume":"22","author":"Mitry","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archopht.1994.01090200063023","article-title":"Digital indocyanine green videoangiography of central serous chorioretinopathy","volume":"112","author":"Guyer","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/srep16204","article-title":"Pachychoroid neovasculopathy and age-related macular degeneration","volume":"5","author":"Miyake","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100144_bib67","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","article-title":"Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes","volume":"3","author":"Hata","year":"2019","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2025.100144_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","article-title":"Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability","volume":"155","author":"Koizumi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10384-015-0387-z","article-title":"Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability","volume":"59","author":"Nomura","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib70","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","article-title":"Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy","volume":"156","author":"Cho","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib71","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","article-title":"Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy","volume":"38","author":"Yanagi","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","article-title":"Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: A 12-month prospective study","volume":"164","author":"Ting","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","article-title":"Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results","volume":"123","author":"Koizumi","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib74","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/bjophthalmol-2013-304555","article-title":"Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy","volume":"98","author":"Hikichi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib75","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2147\/OPTH.S50634","article-title":"Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis","volume":"7","author":"Miura","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib76","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","article-title":"Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab","volume":"34","author":"Saito","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10384-015-0411-3","article-title":"Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection","volume":"60","author":"Saito","year":"2016","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","article-title":"Evolving treatment paradigms for PCV","volume":"36","author":"Fenner","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2025.100144_bib81","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","article-title":"Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100144_bib82","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib83","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2025.100144_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","author":"Arnold-Vangsted","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib85","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib86","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel. Asia Pac","volume":"6","author":"Koh","year":"2017","journal-title":"J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100144_bib87","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","article-title":"Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy","volume":"106","author":"Teo","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib88","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0492-7","article-title":"One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"61","author":"Hosokawa","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib89","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","article-title":"Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy","volume":"255","author":"Morimoto","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib90","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40123-020-00312-3","article-title":"One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"9","author":"Tamachi","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.apjo.2025.100144_bib91","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2025.100144_bib93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40123-023-00843-5","article-title":"Clinical trials and future outlooks of the port delivery system with ranibizumab: a narrative review","volume":"13","author":"Lowater","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.apjo.2025.100144_bib94","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2021.05.029","article-title":"Optical coherence tomography angiography compared with multimodal imaging for diagnosing neovascular central serous chorioretinopathy","volume":"232","author":"Ng","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib95","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/IAE.0000000000001391","article-title":"Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography","volume":"37","author":"Cheung","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib96","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0000000000001702","article-title":"Polypoidal choroidal vasculopathy upon optical coherence tomographic angiography","volume":"38","author":"Chan","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib97","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1097\/IAE.0000000000000777","article-title":"Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization","volume":"35","author":"Inoue","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib98","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajo.2020.05.017","article-title":"A comparison study of polypoidal choroidal vasculopathy imaged with indocyanine green angiography and swept-source optical coherence tomography angiography","volume":"217","author":"Kim","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib99","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/IAE.0000000000002228","article-title":"Improved detection and diagnosis of polypoidal choroidal vasculopathy using a combination of optical coherence tomography and optical coherence tomography angiography","volume":"39","author":"Cheung","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","article-title":"Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management","volume":"38","author":"Cheung","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2025.100144_bib101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/APO.0000000000000584","article-title":"Recent advances in clinical applications of imaging in retinal diseases","volume":"12","author":"Szeto","year":"2023","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"10.1016\/j.apjo.2025.100144_bib102","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00417-020-05051-6","article-title":"Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy","volume":"259","author":"Kim","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib103","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","article-title":"Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy","volume":"40","author":"Chang","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2025.100144_bib104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjo.2021.09.008","article-title":"Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","volume":"58","author":"Jim\u00e9nez-Santos","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.62.2.29","article-title":"Choroidal vascular abnormalities by ultra-widefield indocyanine green angiography in polypoidal choroidal vasculopathy","volume":"62","author":"Jeong","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ceo.13467","article-title":"Choroidal structure in subtypes of polypoidal choroidal vasculopathy determined by binarization of optical coherence tomographic images","volume":"47","author":"Liu","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100292","article-title":"Joint multimodal deep learning-based automatic segmentation of indocyanine green angiography and OCT images for assessment of polypoidal choroidal vasculopathy biomarkers","volume":"3","author":"Loo","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.apjo.2025.100144_bib108","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41598-022-06742-2","article-title":"Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV","volume":"12","author":"Vyas","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2025.100144_bib109","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/bjophthalmol-2020-317537","article-title":"T and genetic variations between Asian and Caucasian polypoidal choroidal vasculopathy","volume":"105","author":"Jordan-Yu","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/OPTH.S337084","article-title":"Class II human leukocyte antigen (HLA) and susceptibility to polypoidal choroidal vasculopathy in Afro-Caribbean descent","volume":"16","author":"Merle","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib111","article-title":"Association between polygenic risk score and one-year outcomes following as-needed aflibercept therapy for exudative age-related macular degeneration","volume":"13","author":"Shijo","year":"2020","journal-title":"Pharm (Basel)"},{"key":"10.1016\/j.apjo.2025.100144_bib112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/bjophthalmol-2020-316195","article-title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","volume":"105","author":"Guimaraes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100096","article-title":"Artificial intelligence for retinal diseases","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100090","article-title":"Latest developments of generative artificial intelligence and applications in ophthalmology","volume":"13","author":"Feng","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00417-019-04493-x","article-title":"Utility of a public-available artificial intelligence in diagnosis of polypoidal choroidal vasculopathy","volume":"258","author":"Yang","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2025.100144_bib116","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1038\/s41598-021-86526-2","article-title":"Deep learning and ensemble stacking technique for differentiating polypoidal choroidal vasculopathy from neovascular age-related macular degeneration","volume":"11","author":"Chou","year":"2021","journal-title":"Sci Rep"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098925000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:33:40Z","timestamp":1740645220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098925000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2162098925000118"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100144","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2025.100144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100144"}}